← United States · Coverage record
US · SEC FORM 4
Kailera Therapeutics, Inc.
KLRA · Nasdaq · CIK 0002096997 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
0 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
SIGNAL HISTORY
Latest recorded score
- 84.4
- 84.4
- 84.4
- 84.4
- 84.4
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -22.1%
- 3M
- -41.9%
- 6M
- —
- 12M
- —
Volatility & liquidity
- Volatility
- 71.8%
- Beta
- —
- Avg daily value
- USD 10.4M
Valuation
- Market cap
- USD 1.5B
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 8,683,381
- Previous report
- 5,962,752
- Avg daily volume
- 1,545,459
- Days to cover
- 5.6
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | Purchase (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC filing ↗ |
| 2026-04-20 | Koppel Adam | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-04-20 | Kaplan Andrew T. | Purchase (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC filing ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | Purchase (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC filing ↗ |
Form 4 evidence
15 transaction lines in the latest 365-day window; 15 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Renaud Ronald C JR | Option exercise / conversion (M) | Common Stock | 38,094 | USD 5.25 | USD 199,994 | SEC filing ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | Purchase (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC filing ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | C (C) | Common Stock | 10,276,820 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (12 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Renaud Ronald C JR | Option exercise / conversion (M) | Common Stock | 38,094 | USD 5.25 | USD 199,994 | SEC filing ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | Purchase (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC filing ↗ |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | C (C) | Common Stock | 10,276,820 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | C (C) | Common Stock | 11,511,852 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Koppel Adam | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-04-20 | Koppel Adam | C (C) | Common Stock | 21,020,768 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Kaplan Andrew T. | Purchase (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC filing ↗ |
| 2026-04-20 | Kaplan Andrew T. | C (C) | Common Stock | 17,857,143 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | Purchase (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC filing ↗ |
| 2026-04-20 | BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P.; Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC | C (C) | Common Stock | 21,020,768 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | Purchase (P) | Common Stock | 8,398,438 | USD 16.00 | USD 134,375,008 | SEC filing ↗ |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP; Bain Capital Fund XIV, L.P.; Bain Capital XIV General Partner, LLC | C (C) | Common Stock | 17,857,143 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | KLRA |
| CIK | 0002096997 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 15 transaction lines from 2026-04-20 to 2026-06-09 5 P purchase lines · 0 S sale lines · 10 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.